A review published in Hereditary Cancer in Clinical Practice reports that evaluating non-coding genomic regions and utilizing whole-genome sequencing could identify pathogenic variants in patients clinically diagnosed with familial adenomatous polyposis who lack detectable coding alterations. While pathogenic variants in the APC gene traditionally underlie familial adenomatous polyposis, standard clinical testing frequently fails to identify coding mutations in a subset of affected individuals.
Multiple colorectal polyposis syndromes—including familial adenomatous polyposis, Peutz-Jeghers syndrome, juvenile polyposis syndrome, PTEN hamartoma tumor syndrome, MUTYH-associated polyposis, NTHL1-associated polyposis, polymerase proofreading-associated polyposis, and MBD4-associated polyposis—share the clinical hallmark of intestinal polyps alongside elevated colorectal cancer risks that can reach up to 100 percent in familial adenomatous polyposis. Undetected pathogenic variants create significant clinical hurdles for patients and family members who face increased disease susceptibility.
Although familial adenomatous polyposis is linked to the 5q21 genomic locus, routine diagnostic sequencing remains predominantly restricted to the APC coding sequence due to clinical cost constraints. Recent investigations indicate that disease-causing alterations in unresolved cases may reside within deep intronic or regulatory regions of APC. Such intronic variants can induce aberrant splicing, pseudoexon formation, and subsequent loss of gene function.
To address these diagnostic gaps, whole-genome sequencing and RNA analysis should be evaluated for patients who present with clinical polyposis but show negative results on standard molecular tests. Expanding molecular diagnostics beyond conventional coding regions enables deeper examination of non-coding regulatory sequences as sequencing technologies advance and associated costs decline.
The authors emphasize that patients presenting with unexplained polyposis must also undergo biallelic MUTYH screening because MUTYH-associated polyposis shares substantial phenotypic overlap with attenuated familial adenomatous polyposis. Although predisposing variants in genes such as NTHL1, MSH3, POLE, POLD1, DSC2, and PIEZO1 contribute to colorectal polyposis, they do not replicate classical familial adenomatous polyposis and should be classified as distinct clinical syndromes rather than alternative etiologies.
Emerging evidence also points to a regulatory contribution from non-coding RNAs, particularly microRNAs and long non-coding RNAs, in disease pathogenesis. Altered microRNA expression observed in polyposis patients without detectable APC mutations indicates that post-transcriptional mechanisms may influence progression. Future research efforts must focus on refining molecular classification criteria, exploring transcriptomic and epigenetic mechanisms, and integrating functional variant studies to resolve missing heritability.
Their analysis demonstrates that even as sequencing technologies expand, investigations on larger clinical populations confirm that pathogenic mutations within the APC and MUTYH genes remain the primary drivers of hereditary polyposis. Evaluating non-canonical cases remains essential because standard testing protocols continue to leave a subset of individuals without a definitive genetic explanation, demonstrating the complexity of polyposis etiology and underscoring the necessity of more sensitive diagnostic methodologies.
A critical consideration highlighted by the authors involves establishing accurate boundaries between familial adenomatous polyposis and related colorectal conditions. Although predisposing variants detected in genes such as NTHL1, MSH3, POLE, POLD1, DSC2, and PIEZO1 are linked to colorectal polyposis, these alterations fail to replicate the full classical disease phenotype. Consequently, the authors conclude that these genetic profiles should not be viewed as alternative causes of classical familial adenomatous polyposis. Instead, clinicians must categorize them as distinct clinical syndromes.
Differentiating between attenuated familial adenomatous polyposis and MUTYH-associated polyposis represents another fundamental diagnostic requirement. Due to substantial phenotypic overlap between attenuated polyposis and MUTYH-associated disease, individuals presenting with unexplained polyposis require thorough screening for biallelic MUTYH pathogenic variants.
The review emphasizes that current clinical testing limitations stem primarily from economic constraints, as routine clinical laboratories frequently restrict sequencing exclusively to the coding sequence of the APC gene. Nevertheless, because familial adenomatous polyposis is linked to the 5q21 genomic locus, the persistent absence of detectable coding mutations in symptomatic individuals indicates that pathogenic alterations often reside within non-coding regulatory sequences or deep intronic regions. Published studies reveal that intronic variants frequently cause aberrant splicing, lead to pseudoexon formation, and ultimately precipitate loss of gene function, confirming that standard coding-only sequencing overlooks crucial pathogenic mechanisms.
To overcome these diagnostic barriers, the authors urge the adoption of comprehensive approaches combining whole-genome sequencing, RNA sequencing, and functional validation for patients who meet clinical polyposis criteria without detectable standard mutations. Furthermore, investigations into non-coding RNAs, specifically microRNAs and long non-coding RNAs, indicate that altered microRNA expression patterns occur in patients lacking detectable APC mutations, pointing toward post-transcriptional regulatory involvement in disease progression. Developing specific non-coding RNA biomarkers could advance earlier detection and yield new therapeutic targets. Expanding clinical diagnostics beyond coding sequences into non-coding, transcriptomic, and epigenetic mechanisms represents a vital pathway to resolving unexplained polyposis cases.
Subject of Research: Diagnostic approaches for unexplained familial adenomatous polyposis lacking coding mutations
Article Title: The genetic puzzle of FAP: exploring novel diagnostic approaches for APC/MUTYH-negative case
Article References: Grot, N., Kazimierczyk, M., Szuman, M., Kaczmarek-Ryś, M., Kryszczyńska, A., Dziechciowska, I., Knaur, M., Hnatyszyn, A., Hryhorowicz, S., & Pławski, A. (2025). The genetic puzzle of FAP: exploring novel diagnostic approaches for APC/MUTYH-negative case. Hereditary Cancer in Clinical Practice, 23(1), Article 25. https://doi.org/10.1186/s13053-025-00318-7
Image Credits: AI Generated
DOI: 10.1186/s13053-025-00318-7
Keywords: Familial adenomatous polyposis, APC gene, MUTYH gene, Colorectal cancer, MUTYH-associated polyposis, Attenuated familial adenomatous polyposis, Whole-genome sequencing, RNA sequencing, Deep intronic variants, Peutz-Jeghers syndrome, Juvenile polyposis syndrome, PTEN hamartoma tumor syndrome, NTHL1-associated polyposis, Polymerase proofreading-associated polyposis, Non-coding RNA, MicroRNA, Long non-coding RNA, Pseudoexon formation, Colorectal polyposis
News Source: Juliet Wilcox. (November 21, 2026). Non-coding APC Variants and Whole-Genome Sequencing May Resolve Unexplained Polyposis Cases. Scienmag.



